Tilray Brands, Inc. announced that its Germany-based cultivation facility, Aphria RX GmbH, has received a new cultivation license under Germany’s recently enacted adult-use cannabis legalization law.
Aphria RX, which was originally licensed in 2019 for Germany’s medical cannabis program, is now authorized to cultivate and manufacture a broader range of cannabis products. With this new license, the company will expand its genetics from three strains approved for medical use to 31 strains under the Cannabis Act.
“We are thrilled to receive this license as it will provide greater access to some of the highest quality medical cannabis produced in Germany and enable us to expand the range of treatment options available to patients. We appreciate the trust that the German Government has placed in Tilray, and we are proud of our team for their groundbreaking work in medical cannabis cultivation and patient care,” said Denise Faltischek, Chief Strategy Officer and Head of International for Tilray, in a press release.
Germany’s adult-use cannabis legalization law, which took effect on April 1, removed cannabis from the country’s Narcotics List. Adults aged 18 and older are now allowed to possess and consume cannabis. Although the initial proposal included regulated adult-use sales, lawmakers decided against establishing a fully regulated marketplace at this time.
Currently, cannabis access is largely limited to homegrown supplies. However, new cannabis clubs, launched this month, allow a limited number of members to legally source their cannabis.
Stay updated with daily cannabis business news. Subscribe for more updates.
